Blood advances 2024 Mar 26
Venetoclax-rituximab is active in patients with BTKi-exposed CLL, but durable treatment-free remissions are uncommon.
Related Questions
New answer by Medical Oncologist at Mayo Clinic (July 3, 2024)
We have limited data for cross-study comparison of pirtobrutinib versus venetoclax. In the BRUIN trial, in patients who were cBTKi-exposed and BCL2i-naïve (n=154), the OR...